Cardiovascular Research

The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size.

Authors: C Sesti|||V Florio|||E G Johnson|||R A Kloner

Affiliations: + Expand

Abstract

The aim of this study was to determine, in an animal model, the effects of tadalafil on myocardial infarct size (IS), hemodynamics and regional myocardial blood flow after myocardial ischemia and reperfusion. Patients with erectile dysfunction (ED) often have risk factors for coronary artery disease. Tadalafil, a long-acting inhibitor of the enzyme phosphodiesterase-5 (PDE5), is used for the treatment of ED; there are no previous data regarding tadalafil in the setting of coronary artery occlusion (CAO). Sprague-Dawley male rats were treated with tadalafil or vehicle (10 mg/kg, by gastric gavage), 2 h before a 30 min CAO. Heart rate was comparable between tadalafil and control groups. Tadalafil reduced mean arterial pressure (P=0.009), systolic (P=0.035) and diastolic (P=0.009) blood pressures during ischemia/reperfusion. Tadalafil significantly reduced IS (42+/-2%) versus controls (54+/-3%) (P=0.006). For the first time, we showed that the PDE5 inhibitor, tadalafil, was well tolerated and cardioprotective in the setting of an experimental myocardial infarction, by substantially reducing ischemic cell death.

---

Chemical List

Carbolines|||Phosphodiesterase Inhibitors|||Potassium Channels|||Tadalafil

---

Reference List

J Sex Med. 2004 Sep;1(2):161-7|||Am J Physiol Heart Circ Physiol. 2002 Sep;283(3):H1263-9|||Am J Cardiol. 1999 Feb 15;83(4):576-82, A7|||Basic Res Cardiol. 2005 Mar;100(2):131-8|||J Urol. 1994 Jan;151(1):54-61|||Int J Impot Res. 2005 May-Jun;17(3):209-15|||Am J Cardiol. 2003 Nov 6;92(9A):37M-46M|||Diabetes Care. 2002 Aug;25(8):1336-9|||Hypertension. 2003 May;41(5):1106-10|||Nat Med. 2005 Feb;11(2):214-22|||J Am Coll Cardiol. 2000 Sep;36(3):845-51|||Int J Impot Res. 2004 Jun;16 Suppl 1:S11-4|||Int J Impot Res. 2004 Aug;16(4):350-3|||Cardiovasc Res. 2003 Aug 1;59(2):441-9|||Prog Cardiovasc Dis. 1977 Jul-Aug;20(1):55-79|||J Mol Cell Cardiol. 2004 Feb;36(2):165-73|||J Endocrinol Invest. 2004 Feb;27(2):192-206|||J Am Coll Cardiol. 2004 Apr 7;43(7):1149-53|||Am J Cardiol. 2003 Nov 6;92(9A):9M-18M|||J Urol. 2004 Sep;172(3):1036-41|||BJU Int. 2004 Jun;93(9):1276-81|||Eur Urol. 2005 Feb;47(2):214-20; discussion 220-2|||Circulation. 2004 Nov 9;110(19):3149-55|||Circulation. 1985 Apr;71(4):849A-50A|||Am J Cardiol. 2003 Nov 6;92(9A):47M-57M|||JAMA. 1999 Feb 10;281(6):537-44|||J Am Coll Cardiol. 2004 Jan 21;43(2):179-84